Evotec's Beat Wins RBC's Conviction but Not Deutsche Bank's — and the Loss Forecast Stands

Evotec has given investors something to cheer about, but not yet something to bank on. The German drug developer's preliminary nine-month figures came in ahead of market expectations, yet the company left its full-year guidance untouched — including a forecast that still pencils in a substantial operating loss. That combination is the heart of the story, and it explains why two major banks looked at the same numbers and reached very different conclusions.

A relative win, an absolute loss

Roughly a week ago, Evotec reported group revenue of about €465.0 million and an adjusted group EBITDA of around ?€42.8 million for the first nine months of 2026. Both figures beat consensus, according to the company.

The nuance matters. Clearing a low bar is not the same as turning a profit, and the adjusted operating result remains firmly in negative territory. Anyone reading the beat as proof of a successful turnaround is getting ahead of the evidence. Equally, anyone fixated solely on the loss misses the improvement relative to expectations. The two facts belong side by side.

For the full year, Evotec reiterated group revenue of roughly €570 million to €610 million. No upgrade accompanied the preliminary release, so the existing outlook remains the yardstick. On adjusted group EBITDA, management still expects a loss of around €70 million to €105 million — a forecast that explicitly anticipates negative earnings.

That is the key caveat against over-reading the interim surprise. A smaller loss than feared and a positive result are different economic states, and a brighter market mood should not blur the distinction. The beat has shifted the relationship to expectations; it has not shifted the company's own targets.

Two banks, two verdicts

RBC Capital Markets reaffirmed its "Outperform" rating and €10 price target on 14 October, pointing to the better-than-expected nine-month results and the confirmed annual outlook, according to dpa-AFX. The logic is coherent: positive surprises can justify a more favorable view.

Deutsche Bank Research, by contrast, kept Evotec at "Hold" with a €3.50 target about a week ago. The gap between the two stances argues against any notion of a clear-cut re-rating. Identical business data do not automatically produce identical conclusions. The bullish camp weights the surprise more heavily; the cautious side warns against ignoring the remaining risk. No fuller rationale from Deutsche Bank can be inferred from the rating alone.

Worth keeping in mind: a price target is an analyst's expectation, not a promise from the company — a distinction that should be second nature when the earnings forecast is still negative.

What 5 November must deliver

Evotec plans to publish full third-quarter and nine-month 2026 results on 5 November 2026. That report is the next scheduled opportunity to put the preliminary figures in context.

The most telling detail will be what drove the outperformance. Only that kind of breakdown allows investors to judge whether the surprise says anything meaningful about the underlying business. Simply noting that expectations were exceeded does not substitute for that scrutiny — and the fuller report will also show whether the published results paint a picture consistent with the confirmed outlook.

Netting it out, cautious recognition beats euphoria. Evotec has delivered a positive signal with its preliminary numbers, but durable earnings progress is a tougher ask than a beat against modest expectations. The stock deserves a differentiated look — not a confidence bonus granted on the strength of a lofty price target.